List view / Grid view
Data from a Phase III trial shows high-risk patients treated with bamlanivimab and etesevimab were 70 percent less likely to be hospitalised due to COVID-19.
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
CT-P59, a monoclonal antibody therapy for COVID-19, was found to be particularly effective at reducing recovery times in moderate COVID-19 patients aged 50 plus.
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-300x278.jpg)
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-scaled-e1607955047519.jpg)
Research shows that the antibodies induced by the Pfizer-BioNTech COVID-19 vaccine can neutralise SARS-CoV-2 viruses with the N501Y mutation.
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
The study will determine if the combination of BRII-196 and BRII-198, two investigational antibodies for SARS-CoV-2, can prevent disease progression.
Modern biologics development relies on the screening of 100s - 1000s of monoclonal antibody (mAb) variants to identify lead development candidates with optimal properties such as affinity, specificity, immunogenicity, and glycosylation.
The new COVID-19 test, called RTF-EXPAR, was able to accurately detect the presence of SARS-CoV-2 viral RNA in under five minutes.
Ebanga was approved based on its ability to reduce 28-day mortality in patients with confirmed Ebolavirus infection.
The new quantitative SARS-CoV-2 IgG lab-based serology test developed by Abbott has been given the CE mark.
AbbVie has licensed the SARS-CoV-2 neutralising antibody, 47D11, from Harbour BioMed and Utrecht University and begun clinical trials.
Medicines that utilise nucleic acids, such as DNA and RNA which control genetic information, are called "nucleic acid medicines".
Industry experts share their latest research and developments in pharma.
